DK1434597T3 - Anvendelse af gp130-aktivatorer ved diabetisk neuropati - Google Patents

Anvendelse af gp130-aktivatorer ved diabetisk neuropati

Info

Publication number
DK1434597T3
DK1434597T3 DK02774697.3T DK02774697T DK1434597T3 DK 1434597 T3 DK1434597 T3 DK 1434597T3 DK 02774697 T DK02774697 T DK 02774697T DK 1434597 T3 DK1434597 T3 DK 1434597T3
Authority
DK
Denmark
Prior art keywords
diabetic neuropathy
activators
medicament
prevention
manufacture
Prior art date
Application number
DK02774697.3T
Other languages
English (en)
Inventor
Michel Dreano
Pierre-Alain Vitte
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Application granted granted Critical
Publication of DK1434597T3 publication Critical patent/DK1434597T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
DK02774697.3T 2001-10-11 2002-10-10 Anvendelse af gp130-aktivatorer ved diabetisk neuropati DK1434597T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01123400 2001-10-11
PCT/EP2002/011364 WO2003033015A1 (en) 2001-10-11 2002-10-10 USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY

Publications (1)

Publication Number Publication Date
DK1434597T3 true DK1434597T3 (da) 2012-02-27

Family

ID=8178778

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02774697.3T DK1434597T3 (da) 2001-10-11 2002-10-10 Anvendelse af gp130-aktivatorer ved diabetisk neuropati

Country Status (20)

Country Link
US (3) US7465441B2 (da)
EP (1) EP1434597B1 (da)
JP (1) JP2005505608A (da)
KR (1) KR20050035151A (da)
CN (1) CN1602203A (da)
AT (1) ATE542542T1 (da)
AU (1) AU2002340547B2 (da)
BR (1) BR0213183A (da)
CA (1) CA2463020A1 (da)
DK (1) DK1434597T3 (da)
EA (1) EA006881B1 (da)
ES (1) ES2381341T3 (da)
HR (1) HRP20040292A2 (da)
IL (1) IL161310A0 (da)
MX (1) MXPA04003442A (da)
NO (1) NO20041908L (da)
PL (1) PL369296A1 (da)
WO (1) WO2003033015A1 (da)
YU (1) YU29804A (da)
ZA (1) ZA200402351B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0213183A (pt) * 2001-10-11 2004-08-31 Applied Research Systems Uso de ativadores gp130 em neuropatia diabética
DK1622939T3 (da) 2003-05-13 2012-04-10 Merck Serono Sa Aktive varianter af det IL-18-bindende protein og medicinske anvendelser deraf
IL161672A0 (en) 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
IL161673A0 (en) * 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
AU2011203356B2 (en) * 2004-04-29 2012-03-22 Yeda Research & Development Co., Ltd IL6R/IL6 chimera for therapy of chemotherapy-induced peripheral neuropathy
IL163856A0 (en) * 2004-09-01 2005-12-18 Applied Research Systems Use of IL-6 in vascular complications
EP2142256B1 (en) * 2007-03-30 2015-10-14 Baker Medical Research Institute Treatment of obesity
DE102008057867A1 (de) * 2008-11-18 2010-05-20 B. Braun Melsungen Ag Fettemulsion zur künstlichen Ernährung von schwerkranken Intensivpatienten
CN106924736B (zh) * 2017-05-09 2020-01-03 北京师范大学 gp130抑制剂在制备干预和治疗肥胖导致的血糖代谢疾病产品中的应用
FR3080533A1 (fr) * 2018-04-27 2019-11-01 Enterosys Utilisation de l'il-6 pour le traitement du diabete

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849571A (en) * 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US5300292A (en) * 1991-05-03 1994-04-05 The Regents Of The University Of California Composition and method for treating inflammation
IT1261787B (it) 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
US6479258B1 (en) * 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US5741772A (en) * 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
NZ517184A (en) * 1999-07-13 2004-02-27 Bolder Biotechnology Inc Immunoglobulin fusion proteins that are cytokines or growth factors joined to an Immunoglobulin domain
BR0213183A (pt) * 2001-10-11 2004-08-31 Applied Research Systems Uso de ativadores gp130 em neuropatia diabética

Also Published As

Publication number Publication date
EA200400520A1 (ru) 2004-08-26
CA2463020A1 (en) 2003-04-24
ZA200402351B (en) 2005-03-29
ES2381341T3 (es) 2012-05-25
AU2002340547B2 (en) 2008-04-03
WO2003033015A1 (en) 2003-04-24
EP1434597B1 (en) 2012-01-25
US20100189684A1 (en) 2010-07-29
US20090169506A1 (en) 2009-07-02
BR0213183A (pt) 2004-08-31
NO20041908L (no) 2004-05-10
HRP20040292A2 (en) 2005-06-30
JP2005505608A (ja) 2005-02-24
PL369296A1 (en) 2005-04-18
US20050058623A1 (en) 2005-03-17
YU29804A (sh) 2006-08-17
KR20050035151A (ko) 2005-04-15
ATE542542T1 (de) 2012-02-15
CN1602203A (zh) 2005-03-30
US7465441B2 (en) 2008-12-16
IL161310A0 (en) 2004-09-27
EP1434597A1 (en) 2004-07-07
MXPA04003442A (es) 2004-07-08
US8278286B2 (en) 2012-10-02
EA006881B1 (ru) 2006-04-28

Similar Documents

Publication Publication Date Title
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
DK1411938T3 (da) Anvendelse af cyclopamin til fremstilling af et medikament til behandling af psoriasis
BG66080B1 (bg) Заместени тиоацетамиди
DE60234577D1 (de) Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält
DK1434597T3 (da) Anvendelse af gp130-aktivatorer ved diabetisk neuropati
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
DK1117403T3 (da) MGLUR5-antagonister til behandling af smerte og angst
ATE346614T1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
DE60219005D1 (de) Feste pharmazeutische formulierung enthaltend modafinil
DE59813162D1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
SE0302304D0 (sv) Novel compounds
SE0102716D0 (sv) Novel compounds
EE200400005A (et) Tablett, mis sisaldab vähemalt kahte eristatavat segmenti ning selle kasutamine
ATE309817T1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
TR200402030T4 (tr) İkame edilen I-aminobutan-3-ol-türevleri
EA200300639A1 (ru) Применение sarp-1 для лечения и/или предупреждения склеродермии
SE0102910D0 (sv) New use
DE60110087D1 (de) Verwendung von Carboanhydrase-Inhibitoren zur Prävention von diabetischer Retinopathie bei Diabetikern
MXPA04001205A (es) Compuesto para eliminar y/o mitigar la anhedonia.
SE0101258D0 (sv) Treatment of low back pain and whiplash associated disorder
EP1370697A4 (en) PEROXYREDOXIN-BASED MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV-1 INFECTIONS AND METHODS OF USE
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs
EA200501625A1 (ru) Интерферон-бета при тяжелом остром респираторном синдроме (sars)